Working… Menu

Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01562041
Recruitment Status : Terminated
First Posted : March 23, 2012
Last Update Posted : August 25, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The study is designed to evaluate the use of ETT ECG indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).

Condition or disease Intervention/treatment Phase
Atherosclerotic Coronary Vascular Disease Drug: Ranolazine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease
Study Start Date : March 2012
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Ranolazine

Arm Intervention/treatment
Ranolazine bid (twice a day) for 14 days.
Drug: Ranolazine
twice per day for 14 days
Other Name: Ranexa®

Primary Outcome Measures :
  1. Electrocardiogram interval times adjusted for heart rate [ Time Frame: 14 days (+/- 3 days) ]

Secondary Outcome Measures :
  1. Exercise Duration [ Time Frame: Baseline, Day 1, and Day 15 ]
  2. Time to ischemia [ Time Frame: 14 days (+/-3 days) ]
  3. Time to angina [ Time Frame: 14 days (+/-3 days) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of stable coronary artery disease

Exclusion Criteria:

  • • Inability or unwillingness to participate in multiple exercise treadmill tests and/or any other requirements of this study as assessed by the Investigator.

    • History of chronic atrial fibrillation.

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01562041

Layout table for location information
United States, Florida
Novartis Investigative Site
Jacksonville, Florida, United States, 32216
United States, New York
Novartis Investigative Site
New York, New York, United States, 10021
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01562041    
Other Study ID Numbers: CPJMR0032105
First Posted: March 23, 2012    Key Record Dates
Last Update Posted: August 25, 2020
Last Verified: April 2016

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Cardiovascular disease
Exercise Treadmill Test
Myocardial ischemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Vascular Diseases
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action